ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2396

Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis

Jean-Charles Mourot1, Sai Yan Yuen2, Mihaela Popescu3 and Nicolas Richard4, 1Université de Montréal, Mont-Royal, QC, Canada, 2Maisonneuve-Rosemont Hospital, Mont-Royal, QC, Canada, 3Maisonneuve Rosemont Hospital, Longueuil, QC, Canada, 4Hopital Maisonneuve Rosemont, Montreal, QC, Canada

Meeting: ACR Convergence 2023

Keywords: giant cell arteritis, Ultrasound, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant Cell Arteritis (GCA) poses diagnostic challenges for clinicians as there is no universal gold standard. We hypothesize that launching a Fast-Track Ultrasound (US) clinic by rheumatologists may spare the need for a biopsy. Therefore, we aimed to assess the diagnostic performance of temporal artery (TA) US in this setting.

Methods: In this Canadian monocentric retrospective cross-sectional analysis, 106 subjects were identified from the Fast-Track clinic between 05/2020-05/2022 (99 after exclusion). Each subject had an US of the temporal and axillary arteries according to a standardized protocol for either suspicion of new-onset or relapse of GCA. The pretest probability was calculated using the Southend probability score (high, medium or low). The sensitivity (Sn), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) were calculated using the rheumatologist final diagnosis as the gold standard.

Results: TA US demonstrated a sensitivity of 80.0% [95% confidence interval (CI) 59.3; 93.2% ], a specificity of 91.7% (95% CI 83.2; 97.0%), a PPV of 76.9% (95% CI 60.2; 88.0%), and a NPV of 93.2% (95% CI 86.1; 96.7%). 30, 44, 29 subjects were at high, medium, and low risk, respectively. Of those subgroups, subjects at high risk had higher PPV with a lower NPV, while similar Sn/Sp were observed between all three subgroups (see Table).

Conclusion: Our findings confirm the validity of TA US as a diagnostic tool for GCA and highlight the importance of Fast-Track US clinics. Future studies will inform on the role of TA biopsy in the setting of increasing use of US.

Supporting image 1

Table 1 : Diagnostic performance of the ultrasound of the temporal and axillary arteries for GCA diagnosis

Supporting image 2

Figure 1 : Workflow of the exclusion criteria and summary of the diagnostic performance of US in GCA


Disclosures: J. Mourot: None; S. Yuen: None; M. Popescu: AbbVie/Abbott, 2, Janssen, 2, 12, Speaker fees, Novartis, 2, 12, Speaker fees, UCB, 2; N. Richard: AbbVie/Abbott, 2, 6, AstraZeneca, 2, Eli Lilly, 2, Janssen, 2, 6, Novartis, 2, 6, Pfizer, 2, UCB, 2.

To cite this abstract in AMA style:

Mourot J, Yuen S, Popescu M, Richard N. Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/diagnostic-performance-of-a-newly-launched-canadian-fast-track-ultrasound-clinic-performed-by-rheumatologists-for-diagnosis-of-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-performance-of-a-newly-launched-canadian-fast-track-ultrasound-clinic-performed-by-rheumatologists-for-diagnosis-of-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology